Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Complement System01:27

Complement System

2.4K
The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a...
2.4K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Bioactive enhanced adjuvant chemokine oligonucleotide nanoparticles (BEACONs) for mucosal vaccination against genital herpes.

Science immunology·2026
Same author

Collectin-11, a complement pattern recognition molecule, mediates pulmonary SARS-CoV-2 neutralization and protection.

PLoS pathogens·2026
Same author

Increased MAP-1 and lectin complement activation capacity in Klinefelter syndrome.

The Journal of clinical endocrinology and metabolism·2026
Same author

Collectin-11 regulates osteoclastogenesis and bone maintenance via a complement-dependent mechanism.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

C1q and mannose-binding lectin binding and complement activation across genetically diverse Mycobacterium tuberculosis complex strains.

Journal of immunology (Baltimore, Md. : 1950)·2025
Same author

Humoral Immune Response Following COVID-19 Vaccination in Multifocal Motor Neuropathy and Chronic Inflammatory Demyelinating Polyneuropathy.

Vaccines·2025
Same journal

Sinomenine Regulates the TRIM32/IRF1/TRAF6 Axis to Inhibit Pyroptosis in Atopic Dermatitis.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology·2026
Same journal

Urolithin A Mitigates Renal Fibrosis by Promoting Fatty Acid Oxidation Through Orchestrating β-Catenin Signaling.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology·2026
Same journal

MiR-124 Inhibits Lipid Deposition in Mouse Liver by Targeting the Trib3/Hnf4α Pathway.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology·2026
Same journal

TCN2 Drives Psoriasis-Like Inflammation and Keratinocyte Hyperproliferation, Correlating With IL-1β and STAT3 Activation.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology·2026
Same journal

The Synthetic Melanocortin Agonist NDP-MSH Ameliorates THSD7A-Associated Membranous Nephropathy in an Active Immunization Mouse Model.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology·2026
Same journal

Brain-Derived Neurotrophic Factor and Associated Signaling in Kidney Diseases.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology·2026
查看所有相关文章

相关实验视频

Updated: Jul 13, 2025

Measuring the 50% Haemolytic Complement CH50 Activity of Serum
08:26

Measuring the 50% Haemolytic Complement CH50 Activity of Serum

Published on: March 29, 2010

37.9K

MAP-2:CD55 仿真构造有效调节补体激活.

Lydia González-Del-Barrio1, Laura Pérez-Alós1, Leon Cyranka1

  • 1Laboratory of Molecular Medicine, Department of Clinical Immunology, Section 7631, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology
|October 12, 2023
PubMed
概括
此摘要是机器生成的。

工程融合蛋白,如MAP-2:CD55^1-4,通过准多个途径,提供强大的补充抑制. 这种新的方法显示出开发用于补充驱动炎症疾病的新疗法的希望.

关键词:
CD55 CD55 CD55 CD55 CD55 CD55 CD55 CD55 CD55 CD55 CD55 CD55 CD55 CD55 CD55 CD55 CD55 CD55在MAP-2中,您可以使用MAP-2.补充抑制是补充的抑制.补充法规补充法规的规定.莱克通路的路径

更多相关视频

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.8K
High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

11.9K

相关实验视频

Last Updated: Jul 13, 2025

Measuring the 50% Haemolytic Complement CH50 Activity of Serum
08:26

Measuring the 50% Haemolytic Complement CH50 Activity of Serum

Published on: March 29, 2010

37.9K
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.8K
High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

11.9K

科学领域:

  • 免疫学 免疫学 免疫学
  • 蛋白质工程是指蛋白质工程.

背景情况:

  • 补体系统对于天生的免疫力至关重要,但也与炎症性疾病有关.
  • 目前对补充介导病理的治疗方法有限.
  • MAP-2 抑制了莱克通路,而 CD55 调节了 C3/C5 转化酶活性.

研究的目的:

  • 开发一种新型的嵌合体抑制剂,MAP-2:CD55^1-4,针对多个补充级联级别.
  • 评估与基因抑制剂的原始分子相比,基因抑制剂的体外和体内疗效.

主要方法:

  • 酶不活跃的MAP-2与CD55.5的N端域的融合.
  • 在实验室中评估通过经典路径,乳素路径和替代路径的补充抑制.
  • 使用Aspergillus fumigatus conidia的血液溶解试验和中性粒细胞激活研究.

主要成果:

  • 与单独使用MAP-2或CD55相比,MAP-2:CD55^1-4显著增强了所有三种补充通路的抑制.
  • 当与曼诺结合性莱克复合时,奇美克抑制剂的效能进一步增加.
  • MAP-2:CD55^1-4在血液溶解试验中保护了红细胞,并降低了中性粒细胞激活和细胞化.

结论:

  • 工程融合蛋白代表了开发强效补充抑制剂的有希望的战略.
  • MAP-2:CD55^1-4是一种高度有效的抑制剂,在补充介导疾病中具有潜在的治疗应用.